Michael William Pennington, Ph.D. - Publications

Affiliations: 
Technical Operations AmbioPharm 
Area:
disulfide rich peptides, autoimmune diseases, Kv1.3 channel, ion channel blockers, venomics, peptide synthesis, proteolytic subbstrates and inhibitors
Website:
http://www.ambiopharm.com

87 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Nguyen PT, Nguyen HM, Wagner KM, Stewart R, Singh V, Thapa P, Chen YJ, Lillya MW, Ton AT, Kondo R, Ghetti A, Pennington MW, Hammock B, Griffith TN, Sack JT, et al. Computational design of peptides to target Na1.7 channel with high potency and selectivity for the treatment of pain. Elife. 11. PMID 36576241 DOI: 10.7554/eLife.81727  0.344
2021 Markakis I, Charitakis I, Beeton C, Galani M, Repousi E, Aggeloglou S, Sfikakis PP, Pennington MW, Chandy KG, Poulopoulou C. Kv1.3 Channel Up-Regulation in Peripheral Blood T Lymphocytes of Patients With Multiple Sclerosis. Frontiers in Pharmacology. 12: 714841. PMID 34630091 DOI: 10.3389/fphar.2021.714841  0.31
2020 Ong ST, Bajaj S, Tanner MR, Chang SC, Krishnarjuna B, Ng XR, Morales RAV, Chen MW, Luo D, Patel D, Yasmin S, Ng JJH, Zhuang Z, Nguyen HM, El Sahili A, ... ... Pennington MW, et al. Modulation of Lymphocyte Potassium Channel K1.3 by Membrane-Penetrating, Joint-Targeting Immunomodulatory Plant Defensin. Acs Pharmacology & Translational Science. 3: 720-736. PMID 32832873 DOI: 10.1021/acsptsci.0c00035  0.336
2020 Nguyen HM, di Lucente J, Chen YJ, Cui Y, Ibrahim RH, Pennington MW, Jin LW, Maezawa I, Wulff H. Biophysical basis for Kv1.3 regulation of membrane potential changes induced by P2X4-mediated calcium entry in microglia. Glia. PMID 32525239 DOI: 10.1002/Glia.23847  0.387
2019 Neff RA, Flinspach M, Gibbs A, Shih AY, Minassian NA, Liu Y, Fellows R, Libiger O, Young S, Pennington MW, Hunter MJ, Wickenden AD. Comprehensive engineering of the tarantula venom peptide huwentoxin-IV to inhibit the human voltage-gated sodium channel hNa17. The Journal of Biological Chemistry. PMID 31871053 DOI: 10.1074/Jbc.Ra119.011318  0.368
2019 Tanner MR, Pennington MW, Chauhan SS, Laragione T, Gulko PS, Beeton C. KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis. Arthritis Research & Therapy. 21: 6. PMID 30612588 DOI: 10.1186/S13075-018-1783-9  0.328
2018 Krishnarjuna B, Villegas-Moreno J, Mitchell ML, Csoti A, Peigneur S, Amero C, Pennington MW, Tytgat J, Panyi G, Norton RS. Synthesis, folding, structure and activity of a predicted peptide from the sea anemone Oulactis sp. with an ShKT fold. Toxicon : Official Journal of the International Society On Toxinology. PMID 29772211 DOI: 10.1016/J.Toxicon.2018.05.006  0.545
2018 Tanner MR, Pennington MW, Chamberlain BH, Huq R, Gehrmann EJ, Laragione T, Gulko PS, Beeton C. Targeting KCa1.1 channels with a scorpion venom peptide for the therapy of rat models of rheumatoid arthritis. The Journal of Pharmacology and Experimental Therapeutics. PMID 29453198 DOI: 10.1124/Jpet.117.245118  0.338
2018 Krishnarjuna B, MacRaild CA, Sunanda P, Morales RAV, Peigneur S, Macrander J, Yu HH, Daly M, Raghothama S, Dhawan V, Chauhan S, Tytgat J, Pennington MW, Norton RS. Corrigendum to "Structure, folding and stability of a minimal homologue from Anemonia sulcata of the sea anemone potassium channel blocker ShK" [Peptides 99 (2018) 169-178]. Peptides. PMID 29361315 DOI: 10.1016/J.Peptides.2018.01.008  0.502
2018 Tanner MR, Huq R, Tajhya R, Pennington MW, Laragione T, Gulko PS, Beeton C. Targeting potassium channels in rheumatoid arthritis Toxicon. 149: 86. DOI: 10.1016/J.Toxicon.2017.12.003  0.39
2018 Sunanda P, Krishnarjuna B, Peigneur S, Mitchell ML, Estrada R, Villegas‐Moreno J, Pennington MW, Tytgat J, Norton RS. Identification, chemical synthesis, structure, and function of a new KV1 channel blocking peptide from Oulactis sp. Biopolymers. 110. DOI: 10.1002/Pep2.24073  0.484
2017 Krishnarjuna B, MacRaild CA, Sunanda P, Morales RAV, Peigneur S, Macrander J, Yu HH, Daly M, Raghothama S, Dhawan V, Chauhan S, Tytgat J, Pennington MW, Norton RS. Structure, folding and stability of a minimal homologue from Anemonia sulcata of the sea anemone potassium channel blocker ShK. Peptides. PMID 28993277 DOI: 10.1016/J.Peptides.2017.10.001  0.561
2017 Pennington MW, Czerwinski A, Norton RS. Peptide therapeutics from venom: Current status and potential. Bioorganic & Medicinal Chemistry. PMID 28988749 DOI: 10.1016/J.Bmc.2017.09.029  0.402
2017 Rangaraju S, Raza SA, Pennati A, Deng Q, Dammer EB, Duong D, Pennington MW, Tansey MG, Lah JJ, Betarbet R, Seyfried NT, Levey AI. A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation. Journal of Neuroinflammation. 14: 128. PMID 28651603 DOI: 10.1186/S12974-017-0906-6  0.421
2017 Bergmann R, Kubeil M, Zarschler K, Chhabra S, Tajhya RB, Beeton C, Pennington MW, Bachmann M, Norton RS, Stephan H. Distribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats. Scientific Reports. 7: 3756. PMID 28623364 DOI: 10.1038/S41598-017-03998-X  0.421
2017 Chittoor B, Bankala K, Morales RAW, MacRaild CA, Sadek M, Leung EW, Robinson S, Pennington M, Norton RS. The Single Disulfide-Directed β-Hairpin Fold. Dynamics, Stability and Engineering. Biochemistry. PMID 28437072 DOI: 10.1021/Acs.Biochem.7B00120  0.424
2017 Tanner MR, Pennington MW, Laragione T, Gulko PS, Beeton C. KCa1.1 channels regulate β1 integrin function and cell adhesion in rheumatoid arthritis fibroblast-like synoviocytes. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 28428266 DOI: 10.1096/Fj.201601097R  0.315
2017 Tanner MR, Tajhya RB, Huq R, Gehrmann EJ, Rodarte KE, Atik MA, Norton RS, Pennington MW, Beeton C. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog. Clinical Immunology (Orlando, Fla.). PMID 28389388 DOI: 10.1016/J.Clim.2017.03.014  0.313
2015 Chang SC, Huq R, Chhabra S, Beeton C, Pennington MW, Smith BJ, Norton RS. N-terminally extended analogues of the K(+) channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3. The Febs Journal. 282: 2247-59. PMID 25864722 DOI: 10.1111/Febs.13294  0.526
2015 Pennington MW, Chang SC, Chauhan S, Huq R, Tajhya RB, Chhabra S, Norton RS, Beeton C. Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK. Marine Drugs. 13: 529-42. PMID 25603346 DOI: 10.3390/Md13010529  0.513
2015 Jin L, Boyd BJ, White PJ, Pennington MW, Norton RS, Nicolazzo JA. Buccal mucosal delivery of a potent peptide leads to therapeutically-relevant plasma concentrations for the treatment of autoimmune diseases. Journal of Controlled Release : Official Journal of the Controlled Release Society. 199: 37-44. PMID 25482338 DOI: 10.1016/J.Jconrel.2014.12.001  0.36
2014 Chhabra S, Chang SC, Nguyen HM, Huq R, Tanner MR, Londono LM, Estrada R, Dhawan V, Chauhan S, Upadhyay SK, Gindin M, Hotez PJ, Valenzuela JG, Mohanty B, Swarbrick JD, ... ... Pennington MW, et al. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 28: 3952-64. PMID 24891519 DOI: 10.1096/Fj.14-251967  0.48
2014 Rashid MH, Huq R, Tanner MR, Chhabra S, Khoo KK, Estrada R, Dhawan V, Chauhan S, Pennington MW, Beeton C, Kuyucak S, Norton RS. A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases. Scientific Reports. 4: 4509. PMID 24676092 DOI: 10.1038/Srep04509  0.447
2014 Koshy S, Huq R, Tanner MR, Atik MA, Porter PC, Khan FS, Pennington MW, Hanania NA, Corry DB, Beeton C. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. The Journal of Biological Chemistry. 289: 12623-32. PMID 24644290 DOI: 10.1074/Jbc.M113.517037  0.323
2014 Nguyen HM, Chhabra S, Chang SC, Huq RU, Tanner MR, Londono LM, Gindin M, Hotez PJ, Mohanty B, Iadonato SP, Gutman GA, Beeton C, Pennington MW, Norton RS, Chandy KG. Kv1.3-Blocking Peptides from Parasitic Worms Exhibit Immunomodulatory Function Biophysical Journal. 106: 739a. DOI: 10.1016/J.Bpj.2013.11.4073  0.499
2013 Rashid MH, Heinzelmann G, Huq R, Tajhya RB, Chang SC, Chhabra S, Pennington MW, Beeton C, Norton RS, Kuyucak S. A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation. Plos One. 8: e78712. PMID 24244345 DOI: 10.1371/Journal.Pone.0078712  0.427
2013 Koshy S, Wu D, Hu X, Tajhya RB, Huq R, Khan FS, Pennington MW, Wulff H, Yotnda P, Beeton C. Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. Plos One. 8: e76740. PMID 24146918 DOI: 10.1371/Journal.Pone.0076740  0.302
2013 Ji S, Czerwinski A, Zhou Y, Shao G, Valenzuela F, Sowiński P, Chauhan S, Pennington M, Liu S. (99m)Tc-Galacto-RGD2: a novel 99mTc-labeled cyclic RGD peptide dimer useful for tumor imaging. Molecular Pharmaceutics. 10: 3304-14. PMID 23875883 DOI: 10.1021/Mp400085D  0.348
2012 Pennington MW, Harunur Rashid M, Tajhya RB, Beeton C, Kuyucak S, Norton RS. A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3. Febs Letters. 586: 3996-4001. PMID 23063513 DOI: 10.1016/J.Febslet.2012.09.038  0.479
2012 Chang SC, Galea CA, Leung EW, Tajhya RB, Beeton C, Pennington MW, Norton RS. Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria. Toxicon : Official Journal of the International Society On Toxinology. 60: 840-50. PMID 22659540 DOI: 10.1016/J.Toxicon.2012.05.017  0.498
2012 Tarcha EJ, Chi V, Muñoz-Elías EJ, Bailey D, Londono LM, Upadhyay SK, Norton K, Banks A, Tjong I, Nguyen H, Hu X, Ruppert GW, Boley SE, Slauter R, Sams J, ... ... Pennington MW, et al. Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease. The Journal of Pharmacology and Experimental Therapeutics. 342: 642-53. PMID 22637724 DOI: 10.1124/Jpet.112.191890  0.46
2012 Chi V, Pennington MW, Norton RS, Tarcha EJ, Londono LM, Sims-Fahey B, Upadhyay SK, Lakey JT, Iadonato S, Wulff H, Beeton C, Chandy KG. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon : Official Journal of the International Society On Toxinology. 59: 529-46. PMID 21867724 DOI: 10.1016/J.Toxicon.2011.07.016  0.412
2011 Beeton C, Pennington MW, Norton RS. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. Inflammation & Allergy Drug Targets. 10: 313-21. PMID 21824083 DOI: 10.2174/187152811797200641  0.463
2010 Rangaraju S, Khoo KK, Feng ZP, Crossley G, Nugent D, Khaytin I, Chi V, Pham C, Calabresi P, Pennington MW, Norton RS, Chandy KG. Potassium channel modulation by a toxin domain in matrix metalloprotease 23. The Journal of Biological Chemistry. 285: 9124-36. PMID 19965868 DOI: 10.1074/Jbc.M109.071266  0.45
2009 Rangaraju S, Chi V, Pennington MW, Chandy KG. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis. Expert Opinion On Therapeutic Targets. 13: 909-24. PMID 19538097 DOI: 10.1517/14728220903018957  0.393
2009 Pennington MW, Beeton C, Galea CA, Smith BJ, Chi V, Monaghan KP, Garcia A, Rangaraju S, Giuffrida A, Plank D, Crossley G, Nugent D, Khaytin I, Lefievre Y, Peshenko I, et al. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Molecular Pharmacology. 75: 762-73. PMID 19122005 DOI: 10.1124/Mol.108.052704  0.519
2008 Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, de la Maza LM, Monuki E, Flügel A, Pennington MW, Parker I, et al. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity. 29: 602-14. PMID 18835197 DOI: 10.1016/J.Immuni.2008.07.015  0.341
2008 Beeton C, Smith BJ, Sabo JK, Crossley G, Nugent D, Khaytin I, Chi V, Chandy KG, Pennington MW, Norton RS. The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation. The Journal of Biological Chemistry. 283: 988-97. PMID 17984097 DOI: 10.1074/Jbc.M706008200  0.459
2007 Hu L, Pennington M, Jiang Q, Whartenby KA, Calabresi PA. Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes. Journal of Immunology (Baltimore, Md. : 1950). 179: 4563-70. PMID 17878353 DOI: 10.4049/Jimmunol.179.7.4563  0.334
2007 Durr JA, Blankenship M, Chauhan SS, Pennington MW. Targeted tyrosine iodination in a multi-tyrosine vasopressin analog. Journal of Peptide Science : An Official Publication of the European Peptide Society. 13: 756-61. PMID 17803258 DOI: 10.1002/Psc.890  0.355
2007 Uemura M, Beeton C, Matheu MP, Parker I, Pennington MW, Cahalan MD, Chandy KG. INHIBITING EFFECTOR MEMORY T CELLS WITH SHK(L5), A NOVEL PEPTIDE BLOCKER OF THE KV1.3 POTASSIUM CHANNEL. Journal of Investigative Medicine. 55: S78. DOI: 10.1097/00042871-200701010-00023  0.371
2006 Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America. 103: 17414-9. PMID 17088564 DOI: 10.1073/Pnas.0605136103  0.325
2006 Mullen KM, Rozycka M, Rus H, Hu L, Cudrici C, Zafranskaia E, Pennington MW, Johns DC, Judge SI, Calabresi PA. Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system. Annals of Neurology. 60: 118-27. PMID 16729292 DOI: 10.1002/Ana.20884  0.38
2005 Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KG. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Molecular Pharmacology. 67: 1369-81. PMID 15665253 DOI: 10.1124/Mol.104.008193  0.443
2005 Lauth X, Babon JJ, Stannard JA, Singh S, Nizet V, Carlberg JM, Ostland VE, Pennington MW, Norton RS, Westerman ME. Bass hepcidin synthesis, solution structure, antimicrobial activities and synergism, and in vivo hepatic response to bacterial infections. The Journal of Biological Chemistry. 280: 9272-82. PMID 15546886 DOI: 10.1074/Jbc.M411154200  0.379
2004 Norton RS, Pennington MW, Wulff H. Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases. Current Medicinal Chemistry. 11: 3041-52. PMID 15578998 DOI: 10.2174/0929867043363947  0.478
2004 Wulff H, Knaus HG, Pennington M, Chandy KG. K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. Journal of Immunology (Baltimore, Md. : 1950). 173: 776-86. PMID 15240664 DOI: 10.4049/Jimmunol.173.2.776  0.376
2004 Chandy KG, Wulff H, Beeton C, Pennington M, Gutman GA, Cahalan MD. K+ channels as targets for specific immunomodulation. Trends in Pharmacological Sciences. 25: 280-9. PMID 15120495 DOI: 10.1016/J.Tips.2004.03.010  0.454
2003 Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. The Journal of Clinical Investigation. 111: 1703-13. PMID 12782673 DOI: 10.1172/Jci16921  0.357
2003 Beeton C, Wulff H, Singh S, Botsko S, Crossley G, Gutman GA, Cahalan MD, Pennington M, Chandy KG. A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. The Journal of Biological Chemistry. 278: 9928-37. PMID 12511563 DOI: 10.1074/Jbc.M212868200  0.427
2003 Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG. Erratum: The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS (Journal of Clinical Investigation (2003) 111 (1703-1713)) Journal of Clinical Investigation. 112. DOI: 10.1172/Jci200316921E  0.369
2002 Lanigan MD, Kalman K, Lefievre Y, Pennington MW, Chandy KG, Norton RS. Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3. Biochemistry. 41: 11963-71. PMID 12356296 DOI: 10.1021/Bi026400B  0.491
2002 Singh S, Khaytin I, Botsko S, Crossley G, Plank DK, Lefievre Y, Giuffrida F, Pennington MW. Addition of o-aminobenzoic acid during Fmoc solid phase synthesis of a fluorogenic substrate containing 3-nitrotyrosine Letters in Peptide Science. 9: 221-225. DOI: 10.1007/Bf02538387  0.383
2001 Lanigan MD, Pennington MW, Lefievre Y, Rauer H, Norton RS. Designed peptide analogues of the potassium channel blocker ShK toxin. Biochemistry. 40: 15528-37. PMID 11747428 DOI: 10.1021/Bi011300B  0.552
2001 Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M, Bernard D, Cahalan MD, Chandy KG, Béraud E. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America. 98: 13942-7. PMID 11717451 DOI: 10.1073/Pnas.241497298  0.454
2001 Chandy KG, Cahalan M, Pennington M, Norton RS, Wulff H, Gutman GA. Potassium channels in T lymphocytes: toxins to therapeutic immunosuppressants. Toxicon : Official Journal of the International Society On Toxinology. 39: 1269-76. PMID 11384714 DOI: 10.1016/S0041-0101(01)00120-9  0.427
2001 Lanigan MD, Tudor JE, Pennington MW, Norton RS. A helical capping motif in ShK toxin and its role in helix stabilization. Biopolymers. 58: 422-436. PMID 11180055 DOI: 10.1002/1097-0282(20010405)58:4<422::Aid-Bip1018>3.0.Co;2-T  0.436
2000 Rauer H, Lanigan MD, Pennington MW, Aiyar J, Ghanshani S, Cahalan MD, Norton RS, Chandy KG. Structure-guided transformation of charybdotoxin yields an analog that selectively targets Ca(2+)-activated over voltage-gated K(+) channels. The Journal of Biological Chemistry. 275: 1201-8. PMID 10625664 DOI: 10.1074/Jbc.275.2.1201  0.475
1999 Pennington MW, Lanigan MD, Kalman K, Mahnir VM, Rauer H, McVaugh CT, Behm D, Donaldson D, Chandy KG, Kem WR, Norton RS. Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin. Biochemistry. 38: 14549-58. PMID 10545177 DOI: 10.1021/Bi991282M  0.72
1999 Rauer H, Pennington M, Cahalan M, Chandy KG. Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin. The Journal of Biological Chemistry. 274: 21885-92. PMID 10419508 DOI: 10.1074/Jbc.274.31.21885  0.521
1999 Dunn BM, Pennington MW, Frase DC, Nash K. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem. Biopolymers. 51: 69-77. PMID 10380354 DOI: 10.1002/(Sici)1097-0282(1999)51:1<69::Aid-Bip8>3.0.Co;2-#  0.497
1999 Pray TR, Nomura AM, Pennington MW, Craik CS. Auto-inactivation by cleavage within the dimer interface of Kaposi's sarcoma-associated herpesvirus protease Journal of Molecular Biology. 289: 197-203. PMID 10366498 DOI: 10.1006/Jmbi.1999.2791  0.328
1999 Kem WR, Pennington MW, Norton RS. Sea anemone toxins as templates for the design of immunosuppressant drugs Perspectives in Drug Discovery and Design. 15: 111-129. DOI: 10.1023/A:1017071131670  0.722
1998 Kalman K, Pennington MW, Lanigan MD, Nguyen A, Rauer H, Mahnir V, Paschetto K, Kem WR, Grissmer S, Gutman GA, Christian EP, Cahalan MD, Norton RS, Chandy KG. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. The Journal of Biological Chemistry. 273: 32697-707. PMID 9830012 DOI: 10.1074/Jbc.273.49.32697  0.706
1998 Tudor JE, Pennington MW, Norton RS. Ionisation behaviour and solution properties of the potassium‐channel blocker ShK toxin Febs Journal. 251: 133-141. PMID 9492277 DOI: 10.1046/J.1432-1327.1998.2510133.X  0.447
1997 Ünal A, Pray TR, Lagunoff M, Pennington MW, Ganem D, Craik CS. The protease and the assembly protein of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) Journal of Virology. 71: 7030-7038. PMID 9261433 DOI: 10.1128/Jvi.71.9.7030-7038.1997  0.351
1996 Pennington MW, Mahnir VM, Khaytin I, Zaydenberg I, Byrnes ME, Kem WR. An essential binding surface for ShK toxin interaction with rat brain potassium channels. Biochemistry. 35: 16407-11. PMID 8987971 DOI: 10.1021/bi962463g  0.663
1996 Pennington MW, Mahnir VM, Krafte DS, Zaydenberg I, Byrnes ME, Khaytin I, Crowley K, Kem WR. Identification of three separate binding sites on SHK toxin, a potent inhibitor of voltage-dependent potassium channels in human T-lymphocytes and rat brain. Biochemical and Biophysical Research Communications. 219: 696-701. PMID 8645244 DOI: 10.1006/Bbrc.1996.0297  0.68
1996 Tudor JE, Pallaghy PK, Pennington MW, Norton RS. Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone Nature Structural & Molecular Biology. 3: 317-320. PMID 8599755 DOI: 10.1038/Nsb0496-317  0.458
1996 Dyke TR, Duggan BM, Pennington MW, Byrnes ME, Kem WR, Norton RS. Synthesis and structural characterisation of analogues of the potassium channel blocker charybdotoxin. Biochimica Et Biophysica Acta. 1292: 31-8. PMID 8547346 DOI: 10.1016/0167-4838(95)00182-4  0.695
1996 Kem W, Pennington M, Mahnir V, Byrnes M, Zaydenberg I, Khaytin I, Krafte D, Hill R, de Chastonay J. Identification of essential residues in the potassium channel inhibitor ShK toxin: analysis of monosubstituted analogs Toxicon. 34: 300. DOI: 10.1016/0041-0101(96)80899-3  0.677
1996 Nielsen KR, Pennington MW. Mass spectral analysis of peptides containing nitrobenzyl moieties Letters in Peptide Science. 2: 301-305. DOI: 10.1007/Bf00142243  0.349
1996 Kem WR, Sanyal G, Williams RW, Pennington MW. Secondary structure of ShK toxin, a potassium-channel-blocking peptide Letters in Peptide Science. 3: 69-72. DOI: 10.1007/Bf00126735  0.692
1995 Pennington MW, Byrnes ME, Zaydenberg I, Khaytin I, de Chastonay J, Krafte DS, Hill R, Mahnir VM, Volberg WA, Gorczyca W. Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone. International Journal of Peptide and Protein Research. 46: 354-8. PMID 8567178 DOI: 10.1111/J.1399-3011.1995.Tb01068.X  0.542
1995 Pennington MW. HF cleavage and deprotection procedures for peptides synthesized using a Boc/Bzl strategy. Methods in Molecular Biology (Clifton, N.J.). 35: 41-62. PMID 7894608 DOI: 10.1385/0-89603-273-6:41  0.362
1995 Pennington MW. Solid-phase synthesis of peptides containing the CH2NH reduced bond surrogate. Methods in Molecular Biology (Clifton, N.J.). 35: 241-7. PMID 7894603 DOI: 10.1385/0-89603-273-6:241  0.363
1995 Pennington MW. Solid-phase synthesis of phosphorylated Tyr-peptides by "phosphite triester" phosphorylation. Methods in Molecular Biology (Clifton, N.J.). 35: 195-200. PMID 7894601 DOI: 10.1385/0-89603-273-6:195  0.377
1995 Holskin BP, Bukhtiyarova M, Dunn BM, Baur P, De Chastonay J, Pennington MW. A continuous fluorescence-based assay of human cytomegalovirus protease using a peptide substrate Analytical Biochemistry. 227: 148-155. PMID 7668375 DOI: 10.1006/Abio.1995.1264  0.576
1995 Kem W, Mahnir V, Pennington M. Type 2 sea anemone toxins compete with type 1 sea anemone and scorpion alpha-toxins for binding to nerve sodium channels Toxicon. 33: 268-269. DOI: 10.1016/0041-0101(95)99265-5  0.62
1995 Pohl J, Hubalek F, Byrnes ME, Nielsen KR, Woods A, Pennington MW. Assignment of the three disulfide bonds in ShK toxin: A potent potassium channel inhibitor from the sea anemone Stichodactyla helianthus Letters in Peptide Science. 1: 291-297. DOI: 10.1007/Bf00119770  0.531
1994 Pennington MW, Zadenberg I, Byrnes ME, Norton RS, Kem WR. Synthesis of the cardiac inotropic polypeptide anthopleurin-A. International Journal of Peptide and Protein Research. 43: 463-70. PMID 8070970 DOI: 10.1111/J.1399-3011.1994.Tb00545.X  0.682
1994 Pennington MW, Baur P. A facile method to prepare C-terminal fluorescently labelled peptides by an Fmoc strategy Letters in Peptide Science. 1: 143-148. DOI: 10.1007/Bf00128532  0.398
1993 Pallaghy PK, Duggan BM, Pennington MW, Norton RS. Three-dimensional Structure in Solution of the Calcium Channel Blocker ω-Conotoxin Journal of Molecular Biology. 234: 405-420. PMID 8230223 DOI: 10.1006/Jmbi.1993.1595  0.379
1992 Pennington MW, Festin SM, Maccecchini ML, Kem WR. Synthesis and characterization of a disulfide bond isomer of omega-conotoxin GVIA. Toxicon : Official Journal of the International Society On Toxinology. 30: 755-64. PMID 1509493 DOI: 10.1016/0041-0101(92)90009-T  0.624
1990 Pennington MW, Kem WR, Dunn BM. Synthesis and biological activity of six monosubstituted analogs of a sea anemone polypeptide neurotoxin Peptide Research. 3: 228-232. PMID 2134066  0.687
1990 Pennington MW, Kem WR, Norton RS, Dunn BM. Chemical synthesis of a neurotoxic polypeptide from the sea anemone Stichodactyla helianthus International Journal of Peptide and Protein Research. 36: 335-343. PMID 1981881 DOI: 10.1111/J.1399-3011.1990.Tb01291.X  0.691
1989 Kem WR, Parten B, Pennington MW, Price DA, Dunn BM. Isolation, characterization, and amino acid sequence of a polypeptide neurotoxin occurring in the sea anemone Stichodactyla helianthus Biochemistry. 28: 3483-3489. PMID 2568126 DOI: 10.1021/Bi00434A050  0.69
Show low-probability matches.